Search Results

You are looking at 51 - 60 of 211 items for :

  • Refine by Access: All x
Clear All
Full access

Adverse Events Reported by Patients With Cancer After Administration of a 2-Dose mRNA COVID-19 Vaccine

Rebecca M. Shulman, David S. Weinberg, Eric A. Ross, Karen Ruth, Glenn F. Rall, Anthony J. Olszanski, James Helstrom, Michael J. Hall, Julia Judd, David Y.T. Chen, Robert G. Uzzo, Timothy P. Dougherty, Riley Williams, Daniel M. Geynisman, Carolyn Y. Fang, Richard I. Fisher, Marshall Strother, Erica Huelsmann, Sunil Adige, Peter D. Whooley, Kevin Zarrabi, Brinda Gupta, Pritish Iyer, Melissa McShane, Hilario Yankey, Charles T. Lee, Nina Burbure, Lauren E. Laderman, Julie Giurintano, Samuel Reiss, and Eric M. Horwitz

second vaccine dose. Vaccine recipients were asked to report whether they had experienced any of the following symptoms: tiredness, local pain or swelling at the injection site, joint pain, muscle pain, fever, chills, headache, nausea, or an allergic

Full access

BBCIC Research Network Analysis of First-Cycle Prophylactic G-CSF Use in Patients Treated With High–Neutropenia Risk Chemotherapy

Pamala A. Pawloski, Cara L. McDermott, James H. Marshall, Vanita Pindolia, Catherine M. Lockhart, Catherine A. Panozzo, Jeffrey S. Brown, and Bernadette Eichelberger

identification of inpatient FN diagnoses during the first treatment cycle using ICD-9-CM codes in any position based on the following definitions: (1) narrow: a diagnosis of neutropenia (288.0x) and fever (780.6) on the same day; (2) intermediate: neutropenia

Full access

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020

Featured Updates to the NCCN Guidelines

John A. Thompson, Bryan J. Schneider, Julie Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, Luciano Costa, Marianne Davies, David Dunnington, Marc S. Ernstoff, Matthew Frigault, Benjamin H. Kaffenberger, Matthew Lunning, Suzanne McGettigan, Jordan McPherson, Nisha A. Mohindra, Jarushka Naidoo, Anthony J. Olszanski, Olalekan Oluwole, Sandip P. Patel, Nathan Pennell, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Yinghong Wang, Ryan M. Weight, Alyse Johnson-Chilla, Griselda Zuccarino-Catania, and Anita Engh

, may indicate colitis . However, blood in the stools and/or fever may be because of other causes of gastrointestinal bleeding, such as infection or peptic ulcer disease or bleeding due to tumor . Cough may be due to an upper respiratory infection

Full access

Major Changes in Systemic Therapy for Advanced Melanoma

John A. Thompson

treated) was a much higher incidence of fever. The newest BRAF/MEK inhibitor combination therapy to receive FDA approval is vemurafenib/cobimetinib. The data behind this approval come from the coBRIM clinical trial. 11 , 12 Larkin et al 11 , 12

Full access

Distress Screening and the Integration of Psychosocial Care Into Routine Oncologic Care

Jimmie C. Holland

), spiritual or religious concerns, and physical problems (eg, breathing problems, constipation, fatigue, fever). Patients can complete the form while in a busy waiting room, and those who have a score of 4 or more (moderate or severe distress) should be

Full access

Treatment Options Expanding for Advanced Melanoma

John A. Thompson

, peritoneal signs consistent with perforation, ileus, fever), permanently discontinue ipilimumab, evaluate for bowel perforation, consider endoscopy, and give steroids until improvement, then taper over 1 month. Incorporating PD1 Inhibitors

Full access

Management of Recurrent Acute Lymphoblastic Leukemia With T-Cell Engagement: CAR T, BiTEs, and Beyond

Jae Park

chemotherapy, serious toxicities are associated with immune activation. The main toxicity, explained Dr. Park, is cytokine release syndrome (CRS), which manifests similarly to sepsis and is characterized by fever, hypotension, capillary leak, respiratory

Full access

Emerging Therapeutic Options in Acute Lymphoblastic Leukemia

Presented by: Patrick A. Brown

most rapidly within the first week of therapy, which is the high-risk period for CRS,” said Dr. Brown, who noted that CRS is characterized by fever, hypotension, respiratory compromise, and potentially coagulopathy. Neurologic toxicities are the second

Full access

Agents Make “Preferred List” in Metastatic Melanoma

John A. Thompson

combination is clearly better than monotherapy,” Dr. Thompson noted. While the combination protects against squamous cell carcinoma, dual blockade can produce fever and chills that often require temporary treatment cessation, with lower doses on resumption of

Full access

Neutrophil Biology and the Next Generation of Myeloid Growth Factors

David C. Dale

Ozer H Stoller R . Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer . N Engl J Med 1991 ; 325 : 164 – 170 . 13 Pettengell R Gurney H Radford JA